BioNTech exits PD-L1 development with Genmab as Q2 revenues drop
BioNTech has given Genmab full control of their joint PD-L1 therapy programme, as it recovers from Q2 losses.
Covid-19
MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine
EMA fast-tracks review of AstraZeneca’s sipavibart to stop Covid
CHMP recommends authorisation for Pfizer-BioNTech’s Covid-19 vaccine
Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine
Novavax seeks FDA approval for updated Covid-19 vaccine
Moderna applies for review of updated Covid-19 vaccine
FDA recommends updated Covid-19 vaccines targeting JN.1
